Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Omeros Corp OMER

Healthcare
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of... see more

Recent & Breaking News (NDAQ:OMER)

Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721

Business Wire February 20, 2019

Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA

Business Wire February 14, 2019

Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors

Business Wire February 12, 2019

Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy

Business Wire January 17, 2019

Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018

Business Wire January 14, 2019

Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence

GlobeNewswire January 3, 2019

Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy

Business Wire December 20, 2018

Omeros Announces Research Collaboration with University of Cambridge

Business Wire December 11, 2018

Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Business Wire December 6, 2018

Omeros Announces Additions to Senior Management Team

Business Wire December 3, 2018

New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire November 30, 2018

Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023

Business Wire November 9, 2018

Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023

PR Newswire November 8, 2018

Omeros Corporation Reports Third Quarter 2018 Financial Results

Business Wire November 8, 2018

Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018

Business Wire November 5, 2018

FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Business Wire October 23, 2018

Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy

Business Wire October 1, 2018

Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA®

Business Wire October 1, 2018

Omeros to Present at the 2018 Cantor Global Healthcare Conference

Business Wire September 27, 2018

Omeros to Present at the Morgan Stanley Global Healthcare Conference

Business Wire September 7, 2018